Spectrum raises $25M as it builds on Zevalin, Fusilev franchises to fund oncology pipeline
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals, a US company which markets two oncology products and seeks to develop a broad pipeline, has raised $24.8 million through the exercise of long-term warrants issued in 2005. The warrants were priced at $6.62.